ONC — Oncolytics Biotech Share News
0.000.00%
Last trade - 00:00- CA$138.32m
- CA$123.56m
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
Oncolytics Biotech Inc reports results for the quarter ended December 31 - Earnings Summary
U.S. STOCKS ON THE MOVE-Citigroup, Goldman Sachs, BlackRock
Oncolytics Biotech jumps after pancreatic cancer therapy gets regulatory nod
Brief: Regulatory Approval Clears Path For Oncolytics Biotech® To Advance Promising Pancreatic Cancer Treatment
Brief: Oncolytics Biotech Completes Initial Safety Phase Enrollment For Goblet Trial's New Pancreatic Cancer Cohort
Brief: Oncolytics Biotech Reports Favorable Results For Bracelet-1 Breast Cancer Study
Brief: Oncolytics Biotech Reports Favorable Results For Bracelet-1 Breast Cancer Study
Brief: Sernova Corp. Announces Appointment Of New Chief Executive Officer
Brief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To C$150 Mln
Brief: Oncolytics Biotech Inc Says On Track To Report Overall Survival Results From Randomized Hr+/Her2- Metastatic Breast Cancer Bracelet-1 Trial
Brief: Oncolytics Biotech Announces Productive FDA Type C Meeting
Brief: Oncolytics Biotech Announces Productive FDA Type C Meeting
Brief: Oncolytics Biotech Announces CEO Matt Coffey To Take Medical Leave Of Absence
Brief: Oncolytics Biotech Doses First Patient In Study Of Pelareorep/FOLFIRINOX Combination Therapy In Pancreatic Cancer